NICE Guidelines for Prescribing Naloxegol
Note: The evidence provided does not contain NICE (National Institute for Health and Care Excellence) guidelines specifically. However, I can provide guidance based on the available American Gastroenterological Association (AGA) guidelines and FDA labeling, which represent the highest quality evidence for naloxegol prescribing.
Primary Recommendation
Naloxegol should be prescribed for adult patients with opioid-induced constipation (OIC) who have failed first-line laxative therapy, at a dose of 25 mg once daily on an empty stomach. 1, 2
Prescribing Algorithm
Step 1: Confirm Indication
- Patient must have chronic non-cancer pain (including chronic pain related to prior cancer or its treatment without frequent opioid dose escalation) 2
- Patient must have documented OIC that has not responded adequately to laxatives 1
- Consider using Bowel Function Index (mean score of ease of defecation, incomplete evacuation, and constipation severity on 0-100 scales) to objectively assess laxative failure 1
Step 2: Check Contraindications
Absolute contraindications 2:
- Known or suspected gastrointestinal obstruction or patients at risk of recurrent obstruction
- Concomitant use with strong CYP3A4 inhibitors (clarithromycin, ketoconazole, itraconazole)
- Known serious or severe hypersensitivity to naloxegol
Step 3: Assess for Dose Modifications
Standard dose: 25 mg once daily 2
Reduce to 12.5 mg once daily if 2:
- Renal impairment (creatinine clearance <60 mL/min) - start at 12.5 mg, may increase to 25 mg if tolerated
- Concomitant moderate CYP3A4 inhibitors (diltiazem, erythromycin, verapamil) - avoid if possible; if unavoidable, use 12.5 mg
- Patient does not tolerate 25 mg dose
Avoid use in 2:
- Severe hepatic impairment
Step 4: Discontinue Maintenance Laxatives
- Stop scheduled laxatives before starting naloxegol 2
- May resume laxatives after 3 days if OIC symptoms persist 2
Step 5: Provide Administration Instructions
- Take on empty stomach: at least 1 hour before first meal OR 2 hours after a meal 2
- Avoid grapefruit and grapefruit juice 2
- For patients unable to swallow tablets: may crush and give orally or via nasogastric tube 2
- Discontinue naloxegol if opioid therapy is discontinued 2
Evidence Quality
The AGA provides a strong recommendation with moderate-quality evidence for naloxegol over no treatment in laxative-refractory OIC 1. This is based on multiple phase 3 trials showing naloxegol achieved higher response rates (risk ratio 1.43; 95% CI 1.19-1.71) compared to placebo 1.
Important Caveats
Timing Consideration
- Patients receiving opioids for less than 4 weeks may be less responsive to naloxegol 2
Safety Monitoring
Monitor for 2:
- Opioid withdrawal symptoms - particularly in patients with disrupted blood-brain barrier
- Severe abdominal pain or diarrhea - discontinue if severe symptoms develop; may restart at 12.5 mg if appropriate
- Gastrointestinal perforation - monitor for severe, persistent, or worsening abdominal pain
Common Adverse Effects (≥3%)
Abdominal pain, diarrhea, nausea, flatulence, vomiting, headache 2
Drug Interactions to Avoid
- Strong CYP3A4 inducers (rifampin) - not recommended, as they decrease naloxegol concentrations 2
- Other opioid antagonists - avoid concomitant use due to additive effects and increased opioid withdrawal risk 2
Comparative Context
While naldemedine has higher quality evidence (strong recommendation with high-quality evidence) 1, naloxegol remains a strong option with moderate-quality evidence and is FDA-approved since 2014 as the first PAMORA for OIC management 1. Recent comparative data suggest oral naloxegol is noninferior to subcutaneous methylnaltrexone and costs approximately $193 less per patient 3.